Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer : a cross-sectional study and the implications

Tools

Godói, Isabella Piassi Dias and Sarmento, Túlio Tadeu Rocha and Reis, Edna Afonso and Gargano, Ludmila Peres and Godman, Brian and Acurcio, Francisco de Assis and Alvares-Teodoro, Juliana and Guerra Júnior, Augusto Afonso and Ruas, Cristina Mariano (2022) Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer : a cross-sectional study and the implications. Expert Review of Pharmacoeconomics and Outcomes Research, 22 (1). pp. 119-129. ISSN 1473-7167 (https://doi.org/10.1080/14737167.2021.1931128)

[thumbnail of Godoi-etal-ERPOR-2021-Acceptability-and-willingness-to-pay-for-a-hypothetical-vaccine-against]
Preview
 Text. Filename: Godoi_etal_ERPOR_2021_Acceptability_and_willingness_to_pay_for_a_hypothetical_vaccine_against_.pdf
Accepted Author Manuscript
Download (627kB)| Preview

Abstract

Introduction: The new coronavirus pandemic has appreciably impacted on morbidity and mortality as well as having appreciable economic impact worldwide. New vaccines are a potential way forward to reduce transmission rates and their subsequent impact. In Brazil vaccines are being distributed via the public sector. In the future, vaccines will be available in the private market. Information about consumers' willingness to pay (WTP) for a hypothetical vaccine against SARS CoV-2 can help future price setting discussions. Methods: A cross-sectional study was conducted with consumers in the five regions of Brazil regarding the willingness to pay (WTP) for a hypothetical vaccine against SARS CoV-2 with a 50% efficacy. Results: A total of 1402 individuals over 18 years of age who declared not having COVID-19 at the time of the survey were interviewed. The acceptability for this hypothetical vaccine was 80.7%. In addition, the amount of WTP by Brazilian consumers for a hypothetical SARS CoV-2 vaccine was estimated at US$ 22.18(120.00 BRL). Conclusion: This study can contribute to decision-making to inform potential pricing for a hypothetical SARS CoV-2 vaccine.

CORE (COnnecting REpositories)